Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avutometinib and Defactinib in Pediatric and Young Adult Patients With Refractory or Recurrent Solid Tumors
NCT06104488Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2023
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of avutometinib in solid tumor, central nervous system tumor, plexiform neurofibroma (PN) and 3 more (3 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Safety of avutometinib at 12 months. Started Oct 2023; status: completed.
02
Drugs
avutometinib
03
Conditions
solid tumorcentral nervous system tumorplexiform neurofibroma (PN)gliomaoptic pathway glioma (OPG)
Beyond the preview
Go deeper on NCT06104488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06104488.